MitoCareX Bio

A drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).

Health Tech & Life Sciences
Acquired by N2OFF Inc.
Acquired Tel-Aviv-Jaffa, Israel Founded 2022
Last updated 2026-07-20
Total raised
$500K
Stage
Acquired
Founded
2022
Headcount
5
HQ
Tel-Aviv-Jaffa, Israel
Sector
Health Tech & Life Sciences

About

MitoCareX Bio is a computationally advanced drug discovery company specializing in the development of novel therapies for hard-to-treat cancers. The company utilizes a computationally advanced drug discovery platform, including its MITOLINE™ algorithm, to model, predict, and discover small molecules that target mitochondrial carriers (SLC25 protein family). Their innovative approach combines computational chemistry, structural biology, and precision medicine to accelerate the discovery of next-generation cancer therapeutics, with an initial focus on lung cancer and an expanded focus on pancreatic cancer. MitoCareX Bio has also expanded its research into inflammatory metabolic diseases.

Funding history · 1 round · $500K total

2022-03
Seed $500K PitchBook, IVC Data & Insights
SciSparc

Q&A

What is MitoCareX Bio's primary focus?
MitoCareX Bio is a drug discovery company focused on developing novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
When was MitoCareX Bio founded?
MitoCareX Bio was founded in February 2022.
What is the current status of MitoCareX Bio?
MitoCareX Bio was acquired by N2OFF in March 2025.
What technology does MitoCareX Bio utilize for drug discovery?
MitoCareX Bio developed its MITOLINE algorithm and advanced computational capabilities to generate reliable 3D models for mitochondrial proteins of interest, which are then used with a cloud-based computational platform to screen small molecules.
How many employees does MitoCareX Bio have?
MitoCareX Bio has 1-10 employees.
Who is the founder of MitoCareX Bio?
Alon Silberman is the Founder & CSO of MitoCareX Bio.
Where is MitoCareX Bio headquartered?
MitoCareX Bio is headquartered in Tel Aviv-Yafo, Israel.

Team · 1

Alon Silberman
Founder · Founder and Chief Scientific Officer

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals

Tags

pharmaceuticalscancercancer-therapyoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitemitocarexbio.com/
LinkedInlinkedin.com/company/81288396/

Identifiers & details

Legal nameMitoCareX Bio Ltd.
Founded2022
Employees (exact)5
Status reasonAcquired by N2OFF on Mar, 2025

Acquisitions & public offerings

Acquired by N2OFF Inc. 2025-10 $700K

Radar intelligence

Web history (Wayback)

Domainmitocarexbio.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516570421
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2022-02-27
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens1
Registry events4 — other (1), charge (1), shares_capital (1), people (1)
Registered addressגורדון 40 גבעתיים

Recent registry events

DateEvent
2025-11-12שינוי בתקנון
2025-12-11רישום שעבוד
2025-11-04העברת מניות
2026-06-03עדכון בעלי תפקידים